Faculty – 10th KOL/Thought Leader Engagement and Advisory Boards Summit


Christopher Alfieri
Thought Leader Liaison, EMD SERONO

view speaker profile

Christopher Alfieri is a Thought Leader Liaison in Neurology & Immunology at EMD Serono. In this role, he has covered KOLs in New York, New Jersey, Pennsylvania, Delaware, and Connecticut. Christopher is responsible for building and maintaining relationships with KOLs based on disease state conversations in the field, at speaker programs and at congresses.

He served EMD Serono in this role for the past four years. Christopher has deep insight into what makes a successful Thought Leader Liaison. He has also driven a number of projects in the field that have changed the dynamic of the KOL relationship.


Howard Berkowitz
Respiratory and Immunology, MSL, U.S. Field-Based Medical Affairs, SANOFI GENZYME


Bryan Bischel
Senior Director, US Medical Affairs, NOTAL VISION


Joseph Chiodo, Senior Medical Director, AGILE THERAPEUTICS

Joseph Chiodo
Senior Medical Director, AGILE THERAPEUTICS

view speaker profile

Joseph A. Chiodo III, PharmD, RPh, earned his B.S. in pharmacy and his PharmD degree at Massachusetts College of Pharmacy in Boston, MA. He completed a post-doctoral industry fellowship at Rutgers, The State University of New Jersey. After completing the fellowship, he worked for Novartis Pharmaceuticals designing and running clinical trials in global clinical development for the bone metabolism therapeutic area. Building on his development experience, Dr. Chiodo followed an approved osteoporosis product into the market and joined the medical affairs department at Novartis. He became a medical science liaison in New York and New Jersey. After gaining both development and medical affairs experience, he left Novartis to become a medical director in U.S. Medical Affairs at Otsuka Pharmaceuticals in Princeton, NJ. Currently Dr. Chiodo works at Agile Therapeutics in Princeton, NJ as a senior medical director.


Grant Freidrich
KOL/Relationships Manager, WELLSPECT HEALTHCARE


Robert Geller
VP Medical Affairs, HERON THERAPEUTICS

view speaker profile

Robert B Geller, MD received a B.S. and M.S. in physics from M.I.T., an MD from Harvard Medical School, and then completed a medical residency at the Hospital of the University of Pennsylvania, and a fellowship in medical oncology at the Johns Hopkins Cancer Center. He has held academic positions at the University of Chicago and Emory University as Director, Stem Cell Transplantation Program, and the Leukemia Program, respectively, where he was involved with new treatment strategies, supportive care, and drug development for patients with blood cancers for those undergoing stem cell transplants. He has held positions at Vion Pharmaceuticals and Alexion, and is currently Vice President, Medical Affairs, Heron Therapeutics, where he has developed a medical affairs department to support the approval and launch of SUSTOL (granisetron) extended-release injection, and for CINVANTI (polysorbate-free IV aprepitant), and the early development of HTX-011 a polymer of bupivacaine and meloxicam being developed for post-surgical pain.


Deanine Halliman, Ph.D.
Director, North American Medical Affairs Operations, ELEKTA

view speaker profile

Having a passion for medical affairs and a love of science, Deanine Halliman, Ph.D., is a woman on a mission to bring a profound sense of reward to the medical affairs arena. With 10 years of experience as a medical science liaison, her connections to science, clinical studies and healthcare providers has fueled her drive to experience all that medical affairs has to offer. The pursuit of a fulfilling career has led her to her most rewarding, yet challenging, role yet as the head of the North American Brachytherapy Medical Affairs Division at Elekta. With no experience in oncology or radiotherapy, in three years she’s managed to absorb the complexities of the field and move her group from a fledgling player to one that engages with top names and universities. With this role she’s assisting healthcare providers in crafting 21st century evidence-based medicine that is changing the shape of cancer care, and she continues to be excited by the changes happening before her eyes.


Lance Hill
CEO, WITHIN3

view speaker profile

As Chief Executive Officer of Within3, Lance Hill brings his own brand of energy, leadership and vision to the company.

With the belief that deeper engagement among healthcare professionals results in improved healthcare and better patient outcomes, Lance strategizes with global healthcare decision makers on how to integrate digital collaboration solutions into their businesses as an effective new channel of communication.

Prior to joining Within3, Lance served as the Vice President and General Manager of the worldwide Service Oriented Architecture business unit for the webMethods Corporation, an international leader in enterprise software. With annual revenues exceeding $200 million, webMethods was acquired in 2007 by German giant, Software AG, for $546 million.

Recruited directly from the University of Toledo by tech giant IBM, Lance led the design and implementation of global telecommunication networks for Fortune 500 businesses and major healthcare organizations, as well as consulted and lectured on worldwide technology strategies. He also developed training, methodology and best practices for Global Services consultants. Lance subsequently joined a top 10 U.S. financial services firm where he served as the Vice President of Enterprise Engineering and founded its Fusion Technology Group, dedicated to accelerating corporate adoption of new technologies and business processes.

A veteran in the technology industry, Lance dedicates himself to work he strongly believes in — improving healthcare by providing an easy-to-use, always accessible, digital collaboration solution for healthcare professionals and industry leaders to connect, communicate and collaborate.


Brandi Howard
Senior Vice President, Global Clinical Development and Medical Affairs, EVOFEM BIOSCIENCES

view speaker profile

Brandi Howard is the Vice President of Global Medical Affairs for Evofem, Inc. She has more than 13 years of medical affairs and women’s healthcare experience in the pharmaceutical industry. Before joining Evofem, Dr. Howard was Senior Director and head of U.S. Field Medical Affairs at Teva Pharmaceuticals, leading teams across eight therapeutic areas and managed care. In addition, she has been in Medical Affairs roles with increasing responsibilities, both in the U.S. and globally, at Teva Women’s Health including Medical Director, and has led numerous medical launch teams for various women’s health products. She has a doctorate in philosophy from the University of Pennsylvania where her area of research was in adolescent sexual risk behaviors and contraceptive use. Dr. Howard has published widely in journals such as Contraception and Fertility & Sterility.


Daniel Jones
Medical Director and U.S. Lead, EMD SERONO

view speaker profile

Daniel Jones, Ph.D., is Senior Medical Director, Neurology & Immunology at EMD Serono. In his current role, he serves as the US Medical Affairs launch lead for MAVENCLAD (Cladribine Tablets).
Danny joined EMD Serono in January 2018 from Biogen, where he held a number of Medical Director roles of increasing responsibility. Most recently, he served as the Global and US Medical Lead for MS Franchise & Pipeline. Prior to Biogen, Danny was an MSL in epilepsy and movement disorders at Lundbeck, where he served as the field medical lead for Onfi (clobazam).
Danny completed his Ph.D. at UCSF and his postdoctoral fellowship at Duke University Medical Center, where he was awarded grants from NIH and the Epilepsy Foundation; his research has been published in the Journal of Neurophysiology, Nature, and PNAS. He resides in Newton with his wife and four young children.


Peter Kowey
Head of Cardiology, MAIN LINE HEALTH

view speaker profile

Peter R. Kowey, M.D., is a graduate of St Joseph’s University and the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. He completed his residency training in internal medicine at Penn State University and was a Fellow in cardiovascular medicine and research at the Harvard University School of Public Health, the Peter Bent Brigham Hospital, and the West Roxbury VA Hospital. After this training he joined the faculty at the Medical College of Pennsylvania as Director of the CCU and Arrhythmia Program, and rose to the rank of full Professor. He went on to become Chief of the Division of Cardiovascular Diseases at the Lankenau Hospital Main Line Health System and President of the Main Line Health Heart Center and is the William Wikoff Smith Chair in Cardiovascular Research. He also is Professor of Medicine and Clinical Pharmacology at Jefferson Medical College.

Dr. Kowey is a Fellow of several professional organizations, including the Clinical Council of the American Heart Association, the American College of Cardiology, the American College of Physicians, the College of Physicians of Philadelphia, the American College of Chest Physicians, and the American College of Clinical Pharmacology. He was a founding member of the Philadelphia Arrhythmia Group and a charter member of the North American Society of Pacing and Electrophysiology. He has served on numerous committees for each of these organizations, including program and abstract review committees for national and international programs. He spent nine years as a member of the Cardiorenal Drug Advisory Committee and four years on the Cardiovascular Devices Committee of the Food and Drug Administration, and was on the Expert Advisory Panel of the US Pharmacopeial convention. Dr Kowey’s principal area of interest has been cardiac rhythm disturbances. He has been the recipient of more than 150 grants and has authored or co-authored more than 400 papers and scientific reports. His group has participated in a large number of pivotal clinical trials, many directed by Dr. Kowey himself. He is the co-editor of three textbooks regarding cardiac arrhythmia. He is a referee for manuscript review for 25 journals and sits on the editorial boards of the Heart Rhythm Journal and the Journal of Cardiovascular Electrophysiology. He has provided consultation to more than 60 international pharmaceutical companies and chaired several data and safety monitoring boards for clinical trials. While working with industry, he has pioneered the development of many antiarrhythmic drugs and antitachycardia devices that are used around the world for the treatment of patients with life-threatening cardiac rhythm problems. Dr. Kowey also maintains a busy consultative arrhythmia practice and has been recognized as a leader in his field in several international publications. Dr. Kowey and his wife Dorothy live in Bryn Mawr and have three daughters, Susan Kealy, an attorney, Jaime Kowey Shean, an attorney, and Olivia, a law student. His latest venture is novel writing — his first mystery novel, Lethal Rhythm, was published in 2010, Deadly Rhythm published in December 2012, and the third novel published in 2014 and titled, “The Empty Net: A Philip Sarkis Mystery.”


Bob Numerof
VP Medical Affairs, RIGEL PHARMACEUTICALS

view speaker profile

Bob Numerof, PhD, is a medical affairs professional having worked in the medical affairs function at Bayer Healthcare, Baxter, and CSL Behring over the past 10+ years. His roles have included strategy development, medical communications, KOL management, Phase IV/post-marketing study design and implementation, and most recently, field team leadership. Prior to his work in medical affairs, Bob had a research career at the NIH and in the biotech/pharmaceutical industry focusing primarily on immunology and inflammation. He received a PhD in Immunology from Tufts University.


William Soliman
President, Chairman of the Board, ACCREDITATION COUNCIL FOR MEDICAL AFFAIRS

view speaker profile

An experienced senior executive with several years of experience in the Pharmaceutical & Biotechnology industry, Dr. Soliman has held key positions where he was instrumental in launching a variety of innovative platforms in medical affairs. He speaks frequently regarding the ever changing role of medical affairs at most major medical affairs conferences and is currently the Executive Chair of the Accreditation Council for Medical Affairs (ACMA) whose primary mission is to create industry standards and goals for medical affairs professionals.

Dr. Soliman has held key management roles across the industry within medical affairs such as at Eisai, Gilead Sciences, Abbott Laboratories, Boehringer-Ingelheim, and Merck.  Dr. Soliman previously also served as Vice President of Medical & Scientific Affairs at CME LLC, a leading provider of CME to health care providers nationwide. He also has worked on the strategic management consulting side with companies such as Veeva systems, and often provides medical affairs consultancy services for Bain, McKinsey, BCG, Atheneum Partners and Alpha Insights.

He has published extensively & led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes, and obesity where he has collaborated with some of the nation’s top research institutions such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program and the University of Pennsylvania’s Center for Weight & Eating Disorders.  Dr. Soliman was most recently invited to speak at the Center for Medical Technology & Policy’s (CMTP) conference on Comparative Effectiveness Research to help inform payers, healthcare policy makers, physicians and patients on the most effective ways to design clinical trials to better address gaps in medicine. He also recently presented at the 2014 annual American Diabetes Association (ADA) Conference on preventing the progression of type 2 diabetes among pre-diabetic overweight and obese individuals. In 2008, Dr. Soliman published a book entitled The Rise of Chemistry: Implications for Industry & Education. ??

He has also held several academic appointments at Seton Hall University’s School of Health & Medical Sciences, New Jersey City University, Kean University’s College of Natural & Applied Sciences, and Touro Colleges of Osteopathic Medicine, Pharmacy & Physical Therapy teaching a variety of courses including clinical therapeutics, pharmacology, pathophysiology, and epidemiology.

Dr. Soliman earned his PhD, MPhil from Columbia University, his Bachelor’s degree from New York University and a Masters Degree from St. Peter’s University.

Dr. Soliman has served as a board member for the MSL Institute. He is a member of several organizations including the American College of Cardiology (ACC), the American Diabetes Association (ADA), The Obesity Society (TOS), the American Association of Clinical Endocrinology (AACE), the American Society of Bariatric Physicians (ASBP), the American Heart Association (AHA), the Drug Information Association (DIA), and the American Chemical Society (ACS).


Trina Stonner, RN, MSN
President, AVANT HEALTHCARE

view speaker profile

An industry veteran on both the client and clinical sides, today Trina serves both in her role as President. Prior to joining Avant Healthcare in 2010, she spent 15 years with a major Midwest pharmaceutical company. There, Trina led multiple global launch readiness initiatives that included strategic KOL engagement for a cardiovascular product launch, as well as leading peer-to-peer strategy and promotion for a critical care product.

Beginning her career as an advanced practice nurse, Trina earned her Master of Science degree from Saint Louis University. Since then, her broader experience has grown to encompass brand management, medical marketing, clinical research, critical care nursing, and hospital sales. At Avant Healthcare, Trina continues focusing on her professional passion: leading strategic efforts focused on KOLs, including developing training, engagement, and brand/platform measurement plans; crafting personalized and hyper-targeted KOL engagement strategies; and medical marketing integration and launch readiness planning.